论文部分内容阅读
目的探讨左炔诺孕酮宫内缓释系统(LNG-IUS)在子宫内膜异位症患者中的临床应用价值。方法选取110例子宫内膜异位症患者为研究对象,采用随机数字表法将其分为观察组和对照组,各55例,观察组在生理期第3~5天时参考LNG-IUS操作说明书于宫腔内正确放置LNG-IUS;对照组则予以口服米司非酮疗法,经期第1天口服,25 mg/次,1次/d。对比两组受试患者治疗前(T0)、治疗6个月(T1)、治疗12个月(T2)等时段内月经周期、经量、痛经评分等指标变化情况,记录其子宫内膜厚度、子宫大小变化差异,分析药物不良反应发生情况。结果 1T1~T2时,两组患者月经周期同T0时对比差异无统计学意义(P>0.05),两组经量、痛经评分、宫内膜厚度及子宫大小等指标均较T0时显著降低(P<0.05);其中观察组变化幅度大于对照组(P<0.05)。2观察组不良反应发生率为10.91%,对照组为14.55%,差异无统计学意义(P>0.05)。结论将LNG-IUS用于子宫内膜异位症患者中,疗效确切,可有效缓解经期疼痛症状,对促进生理期指标恢复、缩小卵巢内异位症囊肿体积等具有积极意义。
Objective To investigate the clinical value of levonorgestrel-releasing intrauterine system (LNG-IUS) in patients with endometriosis. Methods One hundred and ten patients with endometriosis were selected as study subjects and divided into observation group and control group by random number table method, 55 cases in each group. The observation group was referred to the LNG-IUS operating manual LNG-IUS was placed correctly in the uterine cavity, and mifepristone was given orally in the control group. Oral administration was given on the first day of menstruation, 25 mg once daily. The changes of menstrual cycle, menstrual flow and dysmenorrhea scores in two groups of patients before treatment (T0), 6 months (T1) and 12 months (T2) were compared. The endometrial thickness, Uterine changes in the size of the analysis of adverse drug reactions. Results 1T1 ~ T2, the two groups of patients with menstrual cycle compared with T0 was no significant difference (P> 0.05), two groups by the amount of dysmenorrhea score, endometrial thickness and uterine size and other indicators were significantly lower than T0 P <0.05). The change range of the observation group was larger than that of the control group (P <0.05). The incidence of adverse reactions in the observation group was 10.91% and in the control group was 14.55%, the difference was not statistically significant (P> 0.05). CONCLUSION LNG-IUS is effective in patients with endometriosis, which can effectively relieve menstrual pain and promote the recovery of physiological indexes and reduce the volume of ovarian endometriosis.